Dandelion Health

Name: Dandelion Health
Brand: Dandelion Health

AI Native

Catalyzing the development of clinical AI for everyone

Est 2020|Valuation $62M|Raised $29.9M|10 Ref Customers

LinkedIn 7K|Website|FTEs 20|HQ New York, NY

01Competitive Landscape

Narrative competitive analysis

Where Dandelion Health may be relatively differentiated - Multimodal modality emphasis: the vendor highlights inclusion of raw images, waveforms, and notes linked to longitudinal outcomes, and a marketplace intended to structure those modalities. - Clinical AI workflows: vendor materials focus on use cases for AI developers needing training/validation, bias checks, and evidence to support regulatory submissions. Where competitors may excel - Truveta: public narrative around scale and update frequency, plus a health-system-led architecture and explicit data-quality methodology. - Flatiron: established evidence engine in oncology, demonstrated by a large publication footprint and long-standing industry relationships. - Komodo / IQVIA / Datavant (adjacent competitors): Komodo is strong in patient-journey analytics (often claims-centric); IQVIA provides breadth and global footprint with end-to-end services; Datavant focuses on linkage and connectivity rather than a single curated multimodal dataset. Adoption trend indicators - Dandelion: press and partner announcements indicate a growing consortium and multiple therapeutic focus areas such as cardiometabolic/GLP-1 research. - Flatiron: publicly highlights major publication milestones and an extensive research usage record.

	Dandelion Health	Truveta	Flatiron Health
Starting Price	Not publicly listed (demo/enterprise)	Not publicly listed	Not publicly listed (RWD); EMR product has implementation + subscription fees disclosed at a high level
Primary use case	Multimodal RWD and clinical AI training/validation; emphasis on notes, images, and waveforms and vendor-described regulatory provenance	Large-scale EHR-derived RWD updated frequently; health-system-led model; broad population coverage	Oncology-focused RWD/RWE with curated datasets and a publication footprint
Key Strength	Multimodal depth and a vendor-described marketplace for algorithms; consortium model; explicit bias/validation framing	Public narrative around broad population coverage and frequent updates; standardized data model and data quality focus	Depth in oncology, an established publication record and long-standing relationships with regulators and industry
Key Weakness	Limited public security and compliance transparency; limited public reviews; smaller/earlier footprint versus large incumbents	Pricing and access constraints not transparent publicly; modality depth may vary by use case	Primarily oncology focus; may not fit non-oncology needs; access and cost can be high

01Competitive Landscape

Narrative competitive analysis

Where Dandelion Health may be relatively differentiated

Multimodal modality emphasis: the vendor highlights inclusion of raw images, waveforms, and notes linked to longitudinal outcomes, and a marketplace intended to structure those modalities.
Clinical AI workflows: vendor materials focus on use cases for AI developers needing training/validation, bias checks, and evidence to support regulatory submissions.

Where competitors may excel

Truveta: public narrative around scale and update frequency, plus a health-system-led architecture and explicit data-quality methodology.
Flatiron: established evidence engine in oncology, demonstrated by a large publication footprint and long-standing industry relationships.
Komodo / IQVIA / Datavant (adjacent competitors): Komodo is strong in patient-journey analytics (often claims-centric); IQVIA provides breadth and global footprint with end-to-end services; Datavant focuses on linkage and connectivity rather than a single curated multimodal dataset.

Adoption trend indicators

Dandelion: press and partner announcements indicate a growing consortium and multiple therapeutic focus areas such as cardiometabolic/GLP-1 research.
Flatiron: publicly highlights major publication milestones and an extensive research usage record.

	Dandelion Health	Truveta	Flatiron Health
Starting Price	Not publicly listed (demo/enterprise)	Not publicly listed	Not publicly listed (RWD); EMR product has implementation + subscription fees disclosed at a high level
Primary use case	Multimodal RWD and clinical AI training/validation; emphasis on notes, images, and waveforms and vendor-described regulatory provenance	Large-scale EHR-derived RWD updated frequently; health-system-led model; broad population coverage	Oncology-focused RWD/RWE with curated datasets and a publication footprint
Key Strength	Multimodal depth and a vendor-described marketplace for algorithms; consortium model; explicit bias/validation framing	Public narrative around broad population coverage and frequent updates; standardized data model and data quality focus	Depth in oncology, an established publication record and long-standing relationships with regulators and industry
Key Weakness	Limited public security and compliance transparency; limited public reviews; smaller/earlier footprint versus large incumbents	Pricing and access constraints not transparent publicly; modality depth may vary by use case	Primarily oncology focus; may not fit non-oncology needs; access and cost can be high

Dandelion Health

01Competitive Landscape

Narrative competitive analysis

02Market Map

01Competitive Landscape

Narrative competitive analysis

02Market Map